Please login to the form below

Not currently logged in
Email:
Password:

thyroid cancer

This page shows the latest thyroid cancer news and features for those working in and with pharma, biotech and healthcare.

RET rivals Loxo and Blueprint face off with early-stage data

RET rivals Loxo and Blueprint face off with early-stage data

with BLU-667 for at least 24 weeks, and 49% across all patients with that type of cancer. ... Existing treatment of medullary and papillary thyroid cancer with multi-kinase inhibitors is limited by frequent dose modifications or interruptions due to

Latest news

  • AZ nabs US approval for new leukaemia drug Lumoxiti AZ nabs US approval for new leukaemia drug Lumoxiti

    It has assumed greater importance for the targeted pipeline – which sits alongside AZ’s immuno-oncology R&D – since MEK Inhibitor selumetinib failed late-stage trials in thyroid cancer and lung ... National Cancer Institute (NCI) in the US, the

  • FDA gives Loxo breakthrough tag for second cancer drug FDA gives Loxo breakthrough tag for second cancer drug

    including patients with brain metastases, and a 45% response rate in thyroid cancer. ... said. “Given the many available therapies for NSCLC and medullary thyroid cancer, we are pleased that LOXO-292 has shown encouraging data in refractory patients,

  • Eisai’s Lenvima wins European liver cancer indication Eisai’s Lenvima wins European liver cancer indication

    Eisai’ s Lenvima wins European liver cancer indication. EC green-lights the RTK inhibitor as a first-line treatment. ... Lenvima however, is already on the European market to treat thyroid cancer, but thanks to positive data from the phase III REFLECT

  • New cancer drugs can’t quite plug the revenue hole at AZ New cancer drugs can’t quite plug the revenue hole at AZ

    There was one blip on the pipeline radar for AZ however, as it revealed in its interim update that thyroid cancer candidate selumetinib had failed a phase III trial in thyroid ... cancer. The MEK inhibitor had previously failed in a late-stage lung

  • Loxo, Bayer get quick FDA review for ‘precision’ cancer drug Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

    biomarker, a departure from the usual regulatory route of seeking approval based on the organ or tissue where the cancer starts to grow. ... NTRK fusions are seen in a broad range of tumour types, including various forms of colorectal, lung, thyroid,

More from news
Approximately 10 fully matching, plus 54 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Ipsen paid $200m upfront for the rights (ex-North America &Japan) to commercialise Cometriq for medullary thyroid cancer and other indications. ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal

  • EATRIS and the new age of partnering EATRIS and the new age of partnering

    In a display of its global ambition, EATRIS is joining with Cancer Research UK to bring representatives of the US's National Cancer Institute to a workshop in Brussels in October ... The first one we initiated in this matchmaking process was a bio-marker

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    The company is building on its recent oncology launches of Caprelsa (vandetanib) for medullary thyroid cancer - approved in Europe in 2012 - and Iressa (gefitinib), an epidermal growth factor receptor tyrosine kinase ... 2 trials for NSCLC, and

  • Pharma deals during August 2013 Pharma deals during August 2013

    In 2012 these drugs generated $289.6m in revenue for Onyx. Included in the Onyx clinical pipeline are sorafenib (in phase III for thyroid cancer) also partnered with Bayer and carfilzomib, ... This protracted process is indicative of the now “ holy

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    III, this time for thyroid cancer. ... The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets. “

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics